Metformin, the widely used medication for managing Type 2 diabetes, has been known to lower blood sugar, reduce inflammation, and inhibit tumor growth for over six decades. However, the exact biological processes behind its beneficial effects have remained elusive.
A pioneering investigation conducted by Northwestern Medicine and published in Science Advances has pinpointed mitochondrial complex I as a central target of metformin’s action.
Disrupting Mitochondrial Energy to Control Glucose Levels
The drug operates by interfering with mitochondrial function, the powerhouse of the cell responsible for cell metabolism. Researchers found that metformin blocks mitochondrial complex I, a key part of the electron transport chain, thereby reducing energy generation in specific cells related to disease, while leaving healthy cells largely unaffected.
“Despite the widespread use of metformin, we’ve long been uncertain about how it works,” explained Navdeep Chandel, lead author and faculty at Northwestern University Feinberg School of Medicine. “Our findings establish that the drug lowers blood sugar by inhibiting mitochondrial complex I.”
Genetically Modified Mice Reveal Key Mechanisms
Researchers utilized genetically engineered mice with an insertion of NDI1, an enzyme from yeast that mimics complex I but is resistant to metformin’s effects. Through this model, they observed:
- Metformin caused a notable drop in blood glucose in normal mice.
- Mice producing NDI1 showed diminished responsiveness to metformin, with smaller glucose reductions.
- The partial resistance in these mice indicates that metformin's effects may also involve other biological pathways.
These findings complement previous studies that linked metformin’s inhibition of complex I with reduced tumor growth.
Expanding Uses and Future Directions
Beyond diabetes, metformin has been associated with various health benefits, such as:
- Cancer treatment: Targeting mitochondrial complex I in cancer cells.
- Reducing inflammation: Mitigating pollution-triggered inflammation in animal models.
- Improved outcomes for COVID-19: Early data hints at better survival with metformin treatment.
Evidence strongly supports mitochondrial complex I as a key mediator for metformin’s diverse actions. Earlier research from Chandel’s group also highlighted this mechanism in the drug's anti-cancer properties in cells with metformin transporters.
“The broad range of metformin’s effects—from controlling blood sugar to limiting inflammation and fighting cancer—likely stems, at least partially, from its inhibitory impact on mitochondrial complex I,” Chandel stated, emphasizing the importance of continued investigation into other contributing mechanisms.
A Classic Medication Through a Modern Lens
Originating from compounds in the French lilac plant, metformin has been a foundational treatment for diabetes since the mid-20th century. Its affordability and effectiveness have made it a preferred choice for millions globally. In the US, it is often combined with newer agents such as semaglutides, including Ozempic and Mounjaro.
Over time, multiple hypotheses about metformin’s mode of action have been proposed, but few have received clear, experimental validation until now.
Looking Forward
Confirming mitochondrial complex I as metformin’s main target paves the way for innovative research. Understanding these cellular pathways can help optimize diabetes therapies and potentially repurpose metformin for other illnesses.
“The discovery that metformin acts on mitochondrial complex I integrates its varied therapeutic effects,” Chandel noted, highlighting the potential to harness this knowledge for improving health through mitochondrial targeting.
This publication solves a decades-old puzzle regarding metformin’s biological function and showcases mitochondrial biology as a promising domain for future drug development.
0 comments
Sign in to Comment